BusinessFate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 StageBy Nasdaq OMXDec 11, 2017, 11:13 PM UTC
BusinessFate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling Manufacture of FT500By Nasdaq OMXDec 11, 2017, 9:30 PM UTC
BusinessaTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of DirectorsBy Nasdaq OMXApr 10, 2017, 9:00 PM UTC
BusinessFate Therapeutics Announces First Patient Treated in ProTmune™ PROTECT Clinical Trial for the Prevention of Graft-Versus-Host DiseaseBy Nasdaq OMXJan 5, 2017, 1:00 PM UTC
BusinessFate Therapeutics Reports Third Quarter 2016 Financial ResultsBy Nasdaq OMXNov 7, 2016, 9:01 PM UTC
BusinessFate Therapeutics Announces Oral Presentation on Natural Killer Cell Product Candidate FATE-NK100 at the 2016 ASH Annual MeetingBy Nasdaq OMXNov 3, 2016, 8:59 PM UTC
BusinessFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2016 Financial Results on November 7, 2016By Nasdaq OMXOct 31, 2016, 8:01 PM UTC
BusinessFate Therapeutics Announces Issuance of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell CompositionsBy Nasdaq OMXOct 5, 2016, 12:00 PM UTC
